KPC Pharmaceuticals

KPC Pharmaceuticals Current Assets

The Current Assets of KPC Pharmaceuticals (600422.SS) as of Nov 4, 2026 is 5.30 B CNY. In the previous year, Current Assets was 8.68 B CNY — a change of -39.01% (lower).

Current Assets

5.30 BCNY

YoY

-39.01%

Last updated:

Current Assets of KPC Pharmaceuticals is 2025 5.30 B CNY. Current Assets of KPC Pharmaceuticals was 2024 8.68 B CNY. It decreases by -39.01% lower compared to the previous year.

The KPC Pharmaceuticals Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
4.36 B CNY
Jan 1, 2019
4.96 B CNY
Jan 1, 2020
5.66 B CNY
Jan 1, 2021
6.21 B CNY
Jan 1, 2022
6.96 B CNY
Jan 1, 2023
9.05 B CNY
Jan 1, 2024
8.68 B CNY
Jan 1, 2025
5.30 B CNY
The KPC Pharmaceuticals Current Assets history
YEARCurrent AssetsYoY
5.30 BCNY-39.01%
8.68 BCNY-4.08%
9.05 BCNY+30.09%
6.96 BCNY+12.03%
6.21 BCNY+9.75%
5.66 BCNY+14.23%
4.96 BCNY+13.64%
4.36 BCNY+4.19%
4.18 BCNY+27.77%
3.28 BCNY+12.36%
2.92 BCNY+50.71%
1.93 BCNY-10.39%
2.16 BCNY+40.66%
1.53 BCNY+35.57%
1.13 BCNY+15.60%
979.11 MCNY+20.86%
810.12 MCNY+9.43%
740.31 MCNY-4.03%
771.42 MCNY-13.89%
895.81 MCNY-6.22%
955.23 MCNY-14.97%
1.12 BCNY+80.39%
622.79 MCNY+3.98%
598.95 MCNY-19.44%
743.51 MCNY-6.58%
795.86 MCNY+84.48%
431.41 MCNY+66.04%
259.82 MCNY+40.85%
184.47 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

KPC Pharmaceuticals Stock analysis

What does KPC Pharmaceuticals do? KPC Pharmaceuticals, Inc. generates revenue through the research, development, manufacturing, and international marketing of its diverse drug portfolio. The company sells natural herbal medicines, traditional Chinese medicines, and chemical synthetic drugs, including central nervous system drugs, cardiovascular and cerebrovascular drugs, anti-parasitic drugs, anti-microbial drugs, anti-gout drugs, hormones and endocrine drugs, hemorrhoids medicines, and anti-inflammatory drugs. Its main customers are healthcare providers, hospitals, and pharmaceutical distributors globally. The firm also produces health products and offers medical services as additional revenue streams. The company's product segments are defined by therapeutic categories such as central nervous system treatments, cardiovascular care, and anti-inflammatory solutions. These products target both domestic and international markets, with a focus on traditional Chinese medicine and natural herbal formulations. Sales are driven by wholesale distribution networks and direct commercial partnerships in the pharmaceutical industry. KPC Pharmaceuticals' revenue model combines product sales from its core drug lines with supplementary health product offerings and medical service provision. The business leverages its manufacturing capabilities in Kunming, Yunnan to serve global markets, with a strong emphasis on traditional Chinese medicine and natural herbal medicine segments. The firm's international marketing efforts support its presence in multiple regions. KPC Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about KPC Pharmaceuticals stock

Current Assets of KPC Pharmaceuticals is 5.30 B CNY in 2025.

Current Assets of KPC Pharmaceuticals changed from 8.68 B CNY to 5.30 B CNY, representing a -39.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets KPC Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's KPC Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — KPC Pharmaceuticals

All Key Metrics — KPC Pharmaceuticals